FierceBiotech Radio on the biotech bubble and #FierceMadness

In this bonus episode of FierceBiotech Radio, John Carroll sits down with Bloomberg Intelligence analyst Asthika Goonewardene to discuss the results of an informal survey in which readers weighed in on whether the unprecedented bull market for biotech is sustainable or has transformed into a fragile bubble ready to pop (watch the video here). Then, FiercePharma's Carly Helfand discusses #FierceMadness, a single-elimination tournament of drug names going on over at FiercePharmaMarketing.

Download the episode on iTunes or Stitcher, or listen below--and be sure to subscribe. Let us know what you think by dropping a line to [email protected] And if you missed this week's talk with EP Vantage's Amy Brown, you can find it here.

Suggested Articles

Genentech committed $200 million in upfront and near-term payments, plus up to $515 million in more distant milestones, for the exclusive rights.

Netherlands-based biotech Vico Therapeutics has signed up biopharma veteran Rupert Sandbrink, M.D., Ph.D., as its new chief medical officer.

French biotech Genfit is cutting its way out of its phase 3 NASH disaster in the summer and cresting two new units.